Data supporting "The effect of intensive praziquantel treatment on vaccine-specific responses among schoolchildren in Ugandan schistosomiasis-endemic islands: results of the POPVAC A randomised, controlled trial"

This dataset comprises individual-level data from participants in the POPVAC A randomised controlled trial. POPVAC A was an open-label randomised controlled trial of intensive versus standard intervention against Schistosoma mansoni among schoolchildren (9-17 years) in Koome islands, Uganda (ISRCTN60517191). The aim of the trial was to comprehensively address the hypothesis that Schistosoma mansoni infection causes suppression of responses to unrelated vaccines and that this effect can be reversed by intensive treatment with praziquantel. The trial population was selected to comprise children at intense risk of exposure to Schistosoma mansoni infection in a “hot-spot”, island setting in Lake Victoria, Uganda. A portfolio of vaccines, of potential benefit to the children and comprising live, inert, oral and parenteral, was provided to enable a comprehensive assessment and comparison of effects of intensive treatment of Schistosoma mansoni on immune response to vaccines with different characteristics.

Additional Information

To access the data, requests must be made to the PI (Professor Alison Elliott). The request will be reviewed by the PI together with the POPVAC investigator team, in consultation with the POPVAC steering committee. The request will be reviewed based on scientific value and to ensure there is no overlap with existing work. If the request is approved, before data is shared, ethics approval will need to be obtained in your host institution and a Data Transfer Agreement with the MRC/UVRI and LSHTM Uganda Research Unit must be completed.

Keywords

Schistosoma mansoni, Praziquantel, Vaccine response, Children, Randomised controlled trial